On November 11, 2021 Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, reported that management will participate in a fireside chat at the Jefferies London Healthcare Conference, taking place November 16-19, 2021 (Press release, Immunocore, NOV 11, 2021, View Source [SID1234595191]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available on-demand for attendees during the virtual conference beginning on November 18, 2021. The webcast can also be accessed in the ‘Investors’ section of Immunocore’s website at www.immunocore.com.